| 证券代码 | ACHN.O |
| 证券名称 | 爱克莱恩 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2006-10-26 |
| 首发价格(元) | 11.5 USD |
| 首发数量(股) | 4500000 |
| 首发募资额(元) | 51,750,000.00 USD |
| 首发主承销商 | CIBC World Markets Corp,Cowen and Company, LLC |
| 货币单位 | USD |
| 公司名称 | Achillion Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 300 George Street, New Haven, Connecticut, USA |
| 成立日期 | 1998-08-17 |
| 董事会主席 | David I. Scheer |
| 公司属地 | United States 美国 |
| 公司网址 | www.achillion.com |
| 电话 | +1 (203) 624-6000 |
| 传真 | +1 (203) 624-7003 |
| 公司简介 | Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in the Company’s oral factor D portfolio was discovered in its laboratories and is wholly owned. Achillion is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase 3 and commercialization, the Company plans to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. |